Furthermore, our data reveal that baseline expression of BCL‐2, BCL‐xL or MCL‐1 were not predictive of sensitivity to the BH3‐mimetics tested, similar to studies in hematological malignancies and solid tumors.13, 14. The gene discussed is BCL2L1; the disease is hematologic disorder.